|Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression|
P Kuehl, J Zhang, Y Lin, J Lamba, M Assem, J Schuetz, PB Watkins, ...
Nature genetics 27 (4), 383, 2001
|Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America|
SK Gupta, JA Eustace, JA Winston, II Boydstun, TS Ahuja, RA Rodriguez, ...
Clinical Infectious Diseases 40 (11), 1559-1585, 2005
|The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate …|
BA Ward, JC Gorski, DR Jones, SD Hall, DA Flockhart, Z Desta
Journal of Pharmacology and Experimental Therapeutics 306 (1), 287-300, 2003
|Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity|
N Chalasani, H Aljadhey, J Kesterson, MD Murray, SD Hall
Gastroenterology 126 (5), 1287-1292, 2004
|Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7|
JA Williams, BJ Ring, VE Cantrell, DR Jones, J Eckstein, K Ruterbories, ...
Drug Metabolism and Disposition 30 (8), 883-891, 2002
|The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin|
JC Gorski, DR Jones, BD Haehner‐Daniels, MA Hamman, EM O'Mara Jr, ...
Clinical Pharmacology & Therapeutics 64 (2), 133-143, 1998
|Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily|
JC Gorski, SD Hall, DR Jones, M VandenBranden
Biochemical pharmacology 47 (9), 1643-1653, 1994
|The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity|
Z Wang, JC Gorski, MA Hamman, SM Huang, LJ Lesko, SD Hall
Clinical Pharmacology & Therapeutics 70 (4), 317-326, 2001
|The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants|
J Zhang, P Kuehl, ED Green, JW Touchman, PB Watkins, A Daly, SD Hall, ...
Pharmacogenetics and Genomics 11 (7), 555-572, 2001
|Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis|
N Chalasani, JC Gorski, MS Asghar, A Asghar, B Foresman, SD Hall, ...
Hepatology 37 (3), 544-550, 2003
|The Effect of Echinacea (Echinacea purpurea Root) on Cytochrome P450 Activity in Vivo|
JC Gorski, SM Huang, A Pinto, MA Hamman, JK Hilligoss, NA Zaheer, ...
Clinical Pharmacology & Therapeutics 75 (1), 89-100, 2004
|An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation|
BS Mayhew, DR Jones, SD Hall
Drug Metabolism and Disposition 28 (9), 1031-1037, 2000
|Molecular and physical mechanisms of first-pass extraction|
SD Hall, KE Thummel, PB Watkins, KS Lown, LZ Benet, MF Paine, ...
Drug Metabolism and Disposition 27 (2), 161-166, 1999
|Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw|
AA Khan, GKB Sándor, E Dore, AD Morrison, M Alsahli, F Amin, E Peters, ...
The Journal of rheumatology 35 (7), 1391-1397, 2008
|The interaction between St John's wort and an oral contraceptive|
SD Hall, Z Wang, SM Huang, MA Hamman, N Vasavada, AQ Adigun, ...
Clinical Pharmacology & Therapeutics 74 (6), 525-535, 2003
|Mechanism-based inactivation of CYP3A by HIV protease inhibitors|
CS Ernest, SD Hall, DR Jones
Journal of Pharmacology and Experimental Therapeutics 312 (2), 583-591, 2005
|Effect of St John's wort on the pharmacokinetics of fexofenadine|
Z Wang, MA Hamman, SM Huang, LJ Lesko, SD Hall
Clinical Pharmacology & Therapeutics 71 (6), 414-420, 2002
|The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America|
SW Grimm, HJ Einolf, SD Hall, K He, HK Lim, KHJ Ling, C Lu, AA Nomeir, ...
Drug Metabolism and Disposition 37 (7), 1355-1370, 2009
|Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C|
MA Hamman, GA Thompson, SD Hall
Biochemical pharmacology 54 (1), 33-41, 1997
|Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective|
HM Jones, Y Chen, C Gibson, T Heimbach, N Parrott, SA Peters, ...
Clinical Pharmacology & Therapeutics 97 (3), 247-262, 2015